Chemical inhibitors of RNF103-CHMP3 can directly interrupt its function through various mechanisms, primarily by disrupting cellular processes and pathways that RNF103-CHMP3 is known to be involved with. Concanamycin A and Bafilomycin A1, for example, target the vacuolar-type H+-ATPase (V-ATPase) which is essential for endosomal acidification. This acidification is a prerequisite for the proper functioning of the endosomal sorting complexes required for transport (ESCRT), to which RNF103-CHMP3 contributes. The inhibition of V-ATPase by these chemicals can impede endosomal function, which in turn can inhibit the activity of RNF103-CHMP3 in membrane remodeling and vesicle formation. Similarly, Dynasore disables the GTPase activity of dynamin, a protein involved in the final scission of newly formed vesicles from the membrane. By impeding this scission, Dynasore can influence the ability of RNF103-CHMP3 to participate in ESCRT-related processes.
Other chemicals target the actin cytoskeleton, which plays a critical role in cellular processes such as membrane remodeling and vesicle trafficking that RNF103-CHMP3 is associated with. ML141, CK-666, SMIFH2, and Cytochalasin D are inhibitors that affect various aspects of actin dynamics. ML141 interferes with CDC42, a small GTPase that regulates actin polymerization. CK-666 acts on the Arp2/3 complex, inhibiting its ability to nucleate actin filaments. SMIFH2 disrupts formin-mediated actin assembly, and Cytochalasin D blocks actin polymerization directly. These disruptions to actin dynamics can impede RNF103-CHMP3's involvement in vesicle formation and trafficking. Additionally, Y-27632 inhibits ROCK, a kinase that influences actin organization, which can also lead to the impairment of RNF103-CHMP3's role in cytoskeletal-dependent cellular processes. PD 98059, a MEK inhibitor, and Wortmannin, a PI3K inhibitor, disrupt signaling pathways that indirectly influence cytoskeletal rearrangements and phosphoinositide dynamics, respectively, which are processes important for RNF103-CHMP3's function. Z-VAD-FMK, by inhibiting caspases, can interfere with apoptotic body clearance, a process where RNF103-CHMP3's ESCRT function is important. Finally, Hydroxychloroquine, by increasing endosomal pH, can impair endosomal sorting, thus potentially inhibiting RNF103-CHMP3's role in the ESCRT machinery. Each chemical, by targeting specific cellular functions, can contribute to the functional inhibition of RNF103-CHMP3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Inhibits vacuolar-type H+-ATPase (V-ATPase), which is crucial for endosomal acidification, affecting the function of RNF103-CHMP3 in endosomal sorting complexes required for transport (ESCRT). | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Specifically inhibits V-ATPase, disrupting endosome function and therefore potentially inhibiting RNF103-CHMP3's role in membrane remodeling and vesicle formation. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
GTPase inhibitor that impairs the function of dynamin, which is involved in membrane scission, potentially impacting RNF103-CHMP3's role in ESCRT-related processes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
CDC42 inhibitor which could disrupt actin cytoskeleton organization, thereby potentially inhibiting RNF103-CHMP3's involvement in membrane remodeling and vesicle trafficking. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $315.00 $1020.00 | 5 | |
Inhibitor of the Arp2/3 complex, which can alter actin polymerization, potentially affecting RNF103-CHMP3's role in cytoskeletal dynamics associated with membrane remodeling. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
Inhibits formin-mediated actin assembly, which may impair cytoskeletal rearrangements necessary for RNF103-CHMP3 function in vesicle formation and trafficking. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that can disrupt ERK/MAPK signaling, potentially impairing downstream effects on cytoskeletal dynamics that could influence RNF103-CHMP3 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor that can disrupt actin cytoskeleton organization, potentially inhibiting RNF103-CHMP3's role in cellular processes dependent on cytoskeletal dynamics. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor that can affect endocytosis and vesicle trafficking, potentially inhibiting RNF103-CHMP3's role in those processes by altering phosphoinositide dynamics. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $74.00 | 256 | |
Pan-caspase inhibitor that can affect apoptotic body clearance, potentially impacting RNF103-CHMP3's role in the ESCRT machinery during this process. | ||||||